SCHEMBL5872926

SCHEMBL5872926

Cc1cc(I)ccc1Nc1c(C(=O)O)cc(C(=O)NCCC2CCCN2C)c(F)c1F

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
METAP2 P50579 3/20 0.45
ACKR3 P25106 3/20 0.43
MAP2K1 Q02750 4/20 0.40
MAP2K2 P36507 3/20 0.40
EED O75530 1/20 0.40
CACNA1B Q00975 1/20 0.39
APBA1 Q02410 1/20 0.39
POLR1A O95602 1/20 0.38
CHRM3 P20309 2/20 0.38
IRAK4 Q9NWZ3 1/20 0.37
AURKA O14965 1/20 0.37
ABL1 P00519 1/20 0.37
LCK P06239 1/20 0.37
FGFR1 P11362 1/20 0.37
SRC P12931 1/20 0.37
TNFRSF1A P19438 1/20 0.37
EPHA2 P29317 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5872928 0.97 MEN1 (0.49) MEN1KMT2ATDP1METAP2ACKR3
SCHEMBL5872804 0.81 BCL3 (0.47) MEN1KMT2ATDP1MAP2K1MAP2K2
SCHEMBL5872795 0.81 KMT2A (0.49) MEN1KMT2ATDP1MAP2K1MAP2K2
SCHEMBL5872844 0.80 KMT2A (0.47) MEN1KMT2ATDP1MAP2K1MAP2K2
SCHEMBL5872919 0.80 RAB9A (0.49) KMT2A
SCHEMBL5872857 0.80 BCL3 (0.48) MEN1KMT2ATDP1
SCHEMBL5872761 0.78 MEN1 (0.51) MEN1KMT2ATDP1
SCHEMBL5872831 0.78 MEN1 (0.45) MEN1KMT2ATDP1MAP2K1MAP2K2
SCHEMBL5872807 0.78 MEN1 (0.48) MEN1KMT2ATDP1MAP2K1MAP2K2
SCHEMBL5872848 0.78 TDP1 (0.46) MEN1KMT2ATDP1MAP2K1MAP2K2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7001905-B2 Substituted diarylamines as MEK inhibitors WARNER-LAMBERT COMPANY (US) 2006-02-21 US disclosed
US-20030225076-A1 5-Amide substituted diarylamines as mex inhibitors BIWERSI CATHLIN (US) 2003-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225076-A1 5-Amide substituted diarylamines as mex inhibitors NRAS, MAPK6, MAPK12 MEN1 2841/4885KMT2A 636/4885TDP1 851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.